CIK 0001806310 · Non-accelerated filer<br>Smaller reporting company
Taysha Gene Therapies, Inc.
Sign in to watch- Ticker
- TSHA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 843199512
- Phone
- (214) 612-0000
- Business address
- 3000 PEGASUS PARK DRIVE, SUITE 1430, DALLAS, TX, 75247
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 7 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-03-06 | Session R.A. II 10% owner | Other acquisition | +251,296 | 9,420,842 | ||
| 2023-03-06 | Session R.A. II 10% owner | Returned to the company · Employee Stock Option (right to buy) | −199,500 | 0 | ||
| 2023-02-02 | Alam Kamran Chief Financial Officer | Grant or award | +18,691 | 284,812 | ||
| 2023-02-02 | Alam Kamran Chief Financial Officer | Grant or award · Employee Stock Option (right to buy) | +37,384 | 37,384 | ||
| 2023-02-02 | Alam Kamran Chief Financial Officer | Grant or award · Employee Stock Option (right to buy) | +149,900 | 149,900 | ||
| 2022-12-30 | Nolan Sean P. Chief Executive Officer | Grant or award · Stock Option (right to buy) | +1,106,131 | 1,106,131 | ||
| 2022-12-30 | Nagendran Sukumar President and Head of R&D | Grant or award · Stock Option (right to buy) | +790,093 | 790,093 | ||
| 2022-11-10 | Session R.A. II Director | Grant or award · Employee Stock Option (right to buy) | +199,500 | 199,500 | ||
| 2022-10-31 | Manning Paul B Director | Purchase | +1,500,000 | $2.00 | $3.0M | 1,642,202 |
| 2022-08-23 | Alam Kamran Chief Financial Officer | Sale | −3,325 | $3.47 | $12K | 266,121 |
| 2022-08-22 | Alam Kamran Chief Financial Officer | Sale | −9,717 | $3.50 | $34K | 269,446 |
| 2022-08-19 | Alam Kamran Chief Financial Officer | Sale | −11,482 | $3.75 | $43K | 279,163 |
| 2022-08-18 | Alam Kamran Chief Financial Officer | Sale | −7,476 | $3.87 | $29K | 290,645 |
| 2022-07-06 | PRASAD SUYASH CMO and Head of R&D | Sale | −8,956 | $3.79 | $34K | 530,589 |
| 2022-07-05 | PRASAD SUYASH CMO and Head of R&D | Sale | −3,905 | $3.51 | $14K | 539,545 |
| 2022-07-01 | PRASAD SUYASH CMO and Head of R&D | Sale | −23,923 | $3.53 | $84K | 543,450 |
| 2022-06-30 | PRASAD SUYASH CMO and Head of R&D | Sale | −13,892 | $3.72 | $52K | 567,373 |
| 2022-06-29 | PRASAD SUYASH CMO and Head of R&D | Sale | −12,324 | $3.81 | $47K | 581,265 |
| 2022-06-17 | Sepp-Lorenzino Laura Director | Grant or award · Stock Option (right to buy) | +15,500 | 15,500 | ||
| 2022-06-17 | Donenberg Phillip B. Director | Grant or award · Stock Option (right to buy) | +15,500 | 15,500 |
Page 6 of 9 · 173 trades